Compare Opendoor Technologies Inc (OPEN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Opendoor Technologies Inc vs TG Therapeutics Inc — how do they compare? Opendoor Technologies Inc trades at $2.21 (market cap $2.22B), while TG Therapeutics Inc trades at $54.84 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 3.7× Opendoor Technologies Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Opendoor Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Opendoor Technologies Inc for 33 Days and TG Therapeutics Inc for 16 Days on average.
| OPEN | TGTX | |
|---|---|---|
Market Cap | $2.22B | $8.16B |
Volume | 28,705,892 | 1,735,121 |
Sector | Real Estate | Health |
52-Week High | $9.37 | $59.06 |
52-Week Low | $2.27 | $26.94 |
Typical Hold Time | 33 Days | 16 Days |
Enterprise Value | $3.29B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Opendoor Technologies (OPEN) trades at $2.215, down 2.42% on the day, reflecting ongoing challenges in the iBuying sector. The stock shows bearish technical signals with negative moving averages and oscillators, while fundamentals reveal significant losses with a -46.74% net income margin and -$1.3B net loss in 2025. Recent news highlights mortgage expansion efforts and housing market sensitivity to interest rate fluctuations, with the company aiming for adjusted net income breakeven at a $9B revenue run rate.
Despite trading near analyst consensus price target of $4.92 (122% upside), OPEN faces substantial execution risks amid persistent losses and high debt levels. The bullish case relies on successful mortgage expansion and housing market recovery, but current financial metrics and technical indicators suggest continued volatility. Investors should weigh the significant discount to analyst targets against the company's challenging path to profitability.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
